| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Non-Hodgkin | 45 | 2022 | 261 | 9.660 |
Why?
|
| Multiple Myeloma | 19 | 2023 | 307 | 4.670 |
Why?
|
| Case-Control Studies | 51 | 2022 | 1805 | 1.970 |
Why?
|
| 5-Methylcytosine | 7 | 2023 | 112 | 1.800 |
Why?
|
| Cell-Free Nucleic Acids | 4 | 2022 | 71 | 1.760 |
Why?
|
| Diet | 9 | 2013 | 443 | 1.580 |
Why?
|
| Lymphoma, Follicular | 7 | 2022 | 70 | 1.520 |
Why?
|
| Occupational Exposure | 10 | 2018 | 80 | 1.470 |
Why?
|
| Aged | 84 | 2022 | 18415 | 1.430 |
Why?
|
| Antirheumatic Agents | 3 | 2020 | 54 | 1.420 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 6 | 2019 | 151 | 1.330 |
Why?
|
| Risk Factors | 55 | 2022 | 5417 | 1.330 |
Why?
|
| Vegetables | 6 | 2013 | 45 | 1.280 |
Why?
|
| Translocation, Genetic | 5 | 2009 | 265 | 1.200 |
Why?
|
| Middle Aged | 82 | 2021 | 25028 | 1.170 |
Why?
|
| Feeding Behavior | 6 | 2013 | 324 | 1.080 |
Why?
|
| Female | 106 | 2022 | 44532 | 1.080 |
Why?
|
| Agricultural Workers' Diseases | 5 | 2009 | 18 | 1.050 |
Why?
|
| Humans | 143 | 2023 | 86643 | 1.040 |
Why?
|
| Male | 99 | 2022 | 40965 | 1.040 |
Why?
|
| Aged, 80 and over | 40 | 2021 | 6509 | 1.010 |
Why?
|
| Smoking | 9 | 2014 | 609 | 1.010 |
Why?
|
| Fruit | 4 | 2013 | 75 | 0.990 |
Why?
|
| Life Style | 8 | 2015 | 189 | 0.940 |
Why?
|
| Chromosomes, Human, Pair 18 | 3 | 2008 | 42 | 0.920 |
Why?
|
| Chromosomes, Human, Pair 14 | 3 | 2008 | 49 | 0.910 |
Why?
|
| Adult | 75 | 2021 | 25648 | 0.890 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2022 | 8 | 0.880 |
Why?
|
| Pesticides | 3 | 2009 | 29 | 0.850 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 3 | 2016 | 22 | 0.810 |
Why?
|
| Odds Ratio | 17 | 2021 | 678 | 0.790 |
Why?
|
| Hematologic Neoplasms | 5 | 2016 | 329 | 0.790 |
Why?
|
| Meat | 4 | 2012 | 26 | 0.770 |
Why?
|
| Health Status Disparities | 2 | 2021 | 170 | 0.770 |
Why?
|
| Nebraska | 10 | 2012 | 14 | 0.740 |
Why?
|
| Neoplasms, Second Primary | 2 | 2021 | 252 | 0.730 |
Why?
|
| Body Mass Index | 8 | 2017 | 770 | 0.720 |
Why?
|
| Parkinson Disease | 1 | 2021 | 132 | 0.720 |
Why?
|
| Arthritis, Rheumatoid | 3 | 2018 | 166 | 0.710 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 371 | 0.700 |
Why?
|
| Hematologic Agents | 1 | 2018 | 4 | 0.690 |
Why?
|
| United States | 24 | 2023 | 6672 | 0.680 |
Why?
|
| Filgrastim | 1 | 2018 | 56 | 0.680 |
Why?
|
| SEER Program | 13 | 2022 | 190 | 0.660 |
Why?
|
| Neutropenia | 1 | 2018 | 215 | 0.640 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2020 | 683 | 0.640 |
Why?
|
| Biological Products | 1 | 2020 | 143 | 0.620 |
Why?
|
| Genetic Predisposition to Disease | 9 | 2022 | 2271 | 0.610 |
Why?
|
| Chlamydophila pneumoniae | 6 | 2003 | 12 | 0.600 |
Why?
|
| Inflammasomes | 1 | 2017 | 23 | 0.600 |
Why?
|
| Bronchial Neoplasms | 1 | 2016 | 9 | 0.570 |
Why?
|
| Polyethylene Glycols | 1 | 2018 | 363 | 0.570 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2013 | 35 | 0.560 |
Why?
|
| Autophagy | 1 | 2017 | 149 | 0.530 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2018 | 346 | 0.530 |
Why?
|
| Proportional Hazards Models | 6 | 2020 | 859 | 0.500 |
Why?
|
| Heart Failure | 3 | 2022 | 1204 | 0.490 |
Why?
|
| Alcohol Drinking | 6 | 2013 | 267 | 0.490 |
Why?
|
| Lymphoma | 2 | 2013 | 262 | 0.480 |
Why?
|
| Drug Carriers | 1 | 2014 | 81 | 0.470 |
Why?
|
| Obesity | 5 | 2008 | 963 | 0.470 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2014 | 114 | 0.470 |
Why?
|
| Chromosome Aberrations | 2 | 2020 | 387 | 0.470 |
Why?
|
| Incidence | 11 | 2023 | 1577 | 0.470 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2014 | 80 | 0.470 |
Why?
|
| Doxorubicin | 1 | 2014 | 295 | 0.460 |
Why?
|
| Diet, Western | 1 | 2013 | 37 | 0.450 |
Why?
|
| Occupational Diseases | 4 | 2018 | 55 | 0.450 |
Why?
|
| Phytanic Acid | 1 | 2012 | 3 | 0.450 |
Why?
|
| Kidney Neoplasms | 4 | 2011 | 621 | 0.440 |
Why?
|
| Nitrites | 1 | 2012 | 30 | 0.440 |
Why?
|
| Sex Factors | 12 | 2020 | 1054 | 0.440 |
Why?
|
| Nitrates | 1 | 2012 | 35 | 0.440 |
Why?
|
| Tertiary Care Centers | 1 | 2013 | 94 | 0.430 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 763 | 0.430 |
Why?
|
| Prospective Studies | 12 | 2020 | 4213 | 0.410 |
Why?
|
| Young Adult | 21 | 2021 | 5976 | 0.410 |
Why?
|
| Retrospective Studies | 14 | 2022 | 8489 | 0.400 |
Why?
|
| Diphosphonates | 2 | 2021 | 36 | 0.390 |
Why?
|
| Sunlight | 2 | 2008 | 26 | 0.390 |
Why?
|
| Prognosis | 5 | 2020 | 3679 | 0.390 |
Why?
|
| Follow-Up Studies | 12 | 2018 | 3640 | 0.390 |
Why?
|
| Surveys and Questionnaires | 14 | 2020 | 2501 | 0.380 |
Why?
|
| Frailty | 2 | 2022 | 58 | 0.380 |
Why?
|
| Logistic Models | 10 | 2019 | 1186 | 0.380 |
Why?
|
| Neuroblastoma | 1 | 2014 | 374 | 0.380 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2020 | 860 | 0.370 |
Why?
|
| Genome-Wide Association Study | 7 | 2022 | 1621 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2022 | 2357 | 0.360 |
Why?
|
| Medicare | 7 | 2022 | 410 | 0.360 |
Why?
|
| Carcinoma, Renal Cell | 3 | 2011 | 426 | 0.340 |
Why?
|
| Biomedical Research | 2 | 2023 | 376 | 0.340 |
Why?
|
| Chlamydia Infections | 3 | 2003 | 25 | 0.330 |
Why?
|
| Hodgkin Disease | 3 | 2016 | 177 | 0.330 |
Why?
|
| Lymphoma, B-Cell | 2 | 2022 | 103 | 0.330 |
Why?
|
| Carotid Artery Diseases | 2 | 2013 | 97 | 0.330 |
Why?
|
| Databases, Factual | 4 | 2023 | 814 | 0.320 |
Why?
|
| Adolescent | 23 | 2022 | 8981 | 0.320 |
Why?
|
| Breast Neoplasms | 7 | 2022 | 2903 | 0.310 |
Why?
|
| Hair Dyes | 1 | 2007 | 2 | 0.300 |
Why?
|
| Age Factors | 11 | 2019 | 1851 | 0.290 |
Why?
|
| Vitamins | 1 | 2007 | 81 | 0.290 |
Why?
|
| Comorbidity | 4 | 2021 | 943 | 0.290 |
Why?
|
| Vaccination | 1 | 2008 | 254 | 0.290 |
Why?
|
| Immunity, Humoral | 2 | 2021 | 67 | 0.290 |
Why?
|
| Dietary Fats | 4 | 2012 | 135 | 0.270 |
Why?
|
| Motor Activity | 2 | 2006 | 327 | 0.270 |
Why?
|
| Diet Surveys | 3 | 2013 | 20 | 0.270 |
Why?
|
| Colorectal Neoplasms | 3 | 2004 | 938 | 0.270 |
Why?
|
| Cohort Studies | 9 | 2020 | 2767 | 0.270 |
Why?
|
| Endarterectomy, Carotid | 2 | 2003 | 73 | 0.260 |
Why?
|
| Acetyltransferases | 1 | 2005 | 29 | 0.260 |
Why?
|
| Vitamin D | 1 | 2007 | 261 | 0.260 |
Why?
|
| Glutathione Transferase | 1 | 2005 | 111 | 0.250 |
Why?
|
| Confidence Intervals | 6 | 2008 | 229 | 0.250 |
Why?
|
| Risk | 5 | 2012 | 674 | 0.240 |
Why?
|
| Anthropometry | 3 | 2017 | 74 | 0.230 |
Why?
|
| Europe | 5 | 2014 | 309 | 0.230 |
Why?
|
| South Carolina | 1 | 2023 | 3 | 0.230 |
Why?
|
| Spatial Analysis | 1 | 2023 | 7 | 0.230 |
Why?
|
| New York | 1 | 2023 | 69 | 0.230 |
Why?
|
| Arylamine N-Acetyltransferase | 2 | 2012 | 11 | 0.220 |
Why?
|
| Iowa | 7 | 2011 | 35 | 0.220 |
Why?
|
| Treatment Outcome | 6 | 2021 | 7993 | 0.220 |
Why?
|
| Dietary Fiber | 3 | 2011 | 43 | 0.220 |
Why?
|
| Mucopolysaccharidosis III | 1 | 2022 | 1 | 0.220 |
Why?
|
| Asbestos | 1 | 2002 | 22 | 0.220 |
Why?
|
| Diet Records | 3 | 2013 | 19 | 0.220 |
Why?
|
| Prostate-Specific Antigen | 1 | 2005 | 353 | 0.220 |
Why?
|
| Australia | 4 | 2014 | 99 | 0.220 |
Why?
|
| Rituximab | 3 | 2018 | 116 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 78 | 0.210 |
Why?
|
| North America | 4 | 2014 | 180 | 0.210 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2021 | 3 | 0.210 |
Why?
|
| Health Status | 2 | 2020 | 360 | 0.210 |
Why?
|
| Isoenzymes | 2 | 2012 | 271 | 0.210 |
Why?
|
| Dietary Proteins | 2 | 1999 | 30 | 0.200 |
Why?
|
| Adenoma | 1 | 2004 | 235 | 0.200 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2009 | 114 | 0.200 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2021 | 50 | 0.200 |
Why?
|
| Bone Diseases | 1 | 2021 | 54 | 0.200 |
Why?
|
| Herpesvirus 4, Human | 1 | 2021 | 114 | 0.200 |
Why?
|
| Solvents | 2 | 2018 | 96 | 0.200 |
Why?
|
| Aneurysm | 1 | 2001 | 58 | 0.200 |
Why?
|
| Depression | 2 | 2019 | 473 | 0.200 |
Why?
|
| Polymorphism, Genetic | 1 | 2005 | 819 | 0.200 |
Why?
|
| Bone Density Conservation Agents | 1 | 2021 | 45 | 0.190 |
Why?
|
| Renal Artery | 1 | 2001 | 64 | 0.190 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 1464 | 0.190 |
Why?
|
| Taiwan | 5 | 2022 | 23 | 0.190 |
Why?
|
| Self Report | 2 | 2020 | 288 | 0.190 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2020 | 348 | 0.190 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 71 | 0.190 |
Why?
|
| Genetic Loci | 3 | 2020 | 250 | 0.190 |
Why?
|
| Quality of Life | 4 | 2022 | 1585 | 0.190 |
Why?
|
| Mass Screening | 1 | 2005 | 618 | 0.180 |
Why?
|
| Viral Proteins | 1 | 2021 | 300 | 0.180 |
Why?
|
| Arthritis | 1 | 2020 | 46 | 0.180 |
Why?
|
| Cardiomyopathies | 1 | 2022 | 240 | 0.180 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 231 | 0.180 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 331 | 0.170 |
Why?
|
| Exercise | 4 | 2022 | 315 | 0.170 |
Why?
|
| Stem Cell Transplantation | 1 | 2020 | 183 | 0.170 |
Why?
|
| Colonic Neoplasms | 2 | 2003 | 556 | 0.170 |
Why?
|
| Occupations | 2 | 2016 | 26 | 0.170 |
Why?
|
| Carotid Arteries | 2 | 2013 | 127 | 0.170 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2013 | 579 | 0.170 |
Why?
|
| Hydrocarbons, Aromatic | 1 | 2018 | 3 | 0.170 |
Why?
|
| Interleukin-6 | 1 | 2020 | 256 | 0.170 |
Why?
|
| DNA, Neoplasm | 1 | 2019 | 265 | 0.160 |
Why?
|
| Mental Health | 1 | 2019 | 162 | 0.160 |
Why?
|
| Hip Fractures | 1 | 1999 | 45 | 0.160 |
Why?
|
| Thyroid Neoplasms | 2 | 2013 | 408 | 0.160 |
Why?
|
| Sex Characteristics | 1 | 2020 | 319 | 0.160 |
Why?
|
| Postmenopause | 1 | 1999 | 98 | 0.160 |
Why?
|
| Blood Transfusion | 1 | 2019 | 157 | 0.160 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 165 | 0.160 |
Why?
|
| Information Storage and Retrieval | 1 | 2018 | 120 | 0.160 |
Why?
|
| Sjogren's Syndrome | 2 | 2016 | 30 | 0.160 |
Why?
|
| Infliximab | 2 | 2016 | 151 | 0.160 |
Why?
|
| Cytomegalovirus | 1 | 1997 | 76 | 0.150 |
Why?
|
| Neoplasm Staging | 4 | 2019 | 1939 | 0.150 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 3 | 2009 | 21 | 0.150 |
Why?
|
| Multiple Organ Failure | 1 | 2017 | 53 | 0.150 |
Why?
|
| Up-Regulation | 2 | 2012 | 712 | 0.150 |
Why?
|
| Energy Intake | 2 | 2008 | 98 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2001 | 383 | 0.150 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2017 | 79 | 0.150 |
Why?
|
| Proteolysis | 1 | 2017 | 100 | 0.150 |
Why?
|
| Adenocarcinoma | 3 | 2001 | 1169 | 0.140 |
Why?
|
| Epidemiologic Studies | 3 | 2016 | 17 | 0.140 |
Why?
|
| Dementia | 1 | 2018 | 187 | 0.140 |
Why?
|
| Job Description | 1 | 2016 | 8 | 0.140 |
Why?
|
| Carotid Stenosis | 1 | 1997 | 112 | 0.140 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2016 | 20 | 0.140 |
Why?
|
| Cognitive Dysfunction | 1 | 2018 | 132 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 185 | 0.140 |
Why?
|
| Antineoplastic Agents | 4 | 2019 | 2360 | 0.140 |
Why?
|
| Cough | 1 | 2016 | 54 | 0.140 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2016 | 131 | 0.140 |
Why?
|
| Cross-Sectional Studies | 6 | 2011 | 1621 | 0.140 |
Why?
|
| Carcinoma | 3 | 2013 | 436 | 0.140 |
Why?
|
| Dyspnea | 1 | 2016 | 73 | 0.130 |
Why?
|
| Prostatic Neoplasms | 2 | 2005 | 1721 | 0.130 |
Why?
|
| Silicone Gels | 2 | 2008 | 3 | 0.130 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 394 | 0.130 |
Why?
|
| Testosterone | 2 | 2007 | 271 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2014 | 1538 | 0.130 |
Why?
|
| Telomere | 1 | 2016 | 108 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 1 | 2001 | 645 | 0.130 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2019 | 384 | 0.130 |
Why?
|
| Breast Implants | 2 | 2008 | 23 | 0.130 |
Why?
|
| Animals | 14 | 2019 | 26582 | 0.130 |
Why?
|
| Herpesvirus 1, Human | 1 | 1997 | 244 | 0.130 |
Why?
|
| Silk | 1 | 2014 | 1 | 0.130 |
Why?
|
| Major Histocompatibility Complex | 1 | 2015 | 81 | 0.130 |
Why?
|
| Pedigree | 3 | 2007 | 966 | 0.130 |
Why?
|
| Epidemiologic Research Design | 1 | 2014 | 22 | 0.120 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 66 | 0.120 |
Why?
|
| Kidney Transplantation | 1 | 2001 | 849 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 294 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2014 | 116 | 0.120 |
Why?
|
| HLA Antigens | 2 | 2014 | 232 | 0.120 |
Why?
|
| Sepsis | 1 | 2017 | 306 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 1 | 2016 | 927 | 0.120 |
Why?
|
| Agriculture | 2 | 2015 | 38 | 0.120 |
Why?
|
| Nutritive Value | 1 | 2013 | 5 | 0.120 |
Why?
|
| Diet, Vegetarian | 1 | 2013 | 8 | 0.120 |
Why?
|
| Patient Outcome Assessment | 1 | 2014 | 84 | 0.120 |
Why?
|
| Nutrition Assessment | 1 | 2013 | 21 | 0.120 |
Why?
|
| Combined Modality Therapy | 2 | 2014 | 1686 | 0.110 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 136 | 0.110 |
Why?
|
| Bacterial Infections | 1 | 2015 | 182 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2016 | 582 | 0.110 |
Why?
|
| Tumor Burden | 1 | 2014 | 289 | 0.110 |
Why?
|
| Factor Analysis, Statistical | 1 | 2013 | 111 | 0.110 |
Why?
|
| Receptor, Endothelin A | 1 | 2012 | 22 | 0.110 |
Why?
|
| Liver Neoplasms | 1 | 2019 | 736 | 0.110 |
Why?
|
| Endothelins | 1 | 2012 | 35 | 0.110 |
Why?
|
| Meat Products | 1 | 2012 | 7 | 0.110 |
Why?
|
| Multivariate Analysis | 5 | 2012 | 999 | 0.110 |
Why?
|
| Oleic Acid | 1 | 2012 | 14 | 0.110 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2012 | 33 | 0.110 |
Why?
|
| Ovulation Inhibition | 1 | 2012 | 3 | 0.110 |
Why?
|
| Femoral Artery | 1 | 2013 | 81 | 0.110 |
Why?
|
| Mutagens | 1 | 2012 | 31 | 0.110 |
Why?
|
| Reproductive History | 1 | 2012 | 8 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 458 | 0.110 |
Why?
|
| Endothelin-1 | 1 | 2012 | 41 | 0.110 |
Why?
|
| Bell Palsy | 1 | 2012 | 3 | 0.110 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2012 | 18 | 0.110 |
Why?
|
| Graft Survival | 2 | 2010 | 884 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2015 | 428 | 0.110 |
Why?
|
| Leukemia | 2 | 2006 | 320 | 0.110 |
Why?
|
| Cytosine | 2 | 2023 | 127 | 0.110 |
Why?
|
| Quinoxalines | 1 | 2012 | 50 | 0.110 |
Why?
|
| Mice, Nude | 1 | 2014 | 790 | 0.110 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2013 | 54 | 0.110 |
Why?
|
| Environmental Exposure | 2 | 2007 | 296 | 0.110 |
Why?
|
| Dizziness | 1 | 2012 | 27 | 0.110 |
Why?
|
| Cause of Death | 1 | 2013 | 277 | 0.110 |
Why?
|
| Pyelonephritis | 1 | 2012 | 9 | 0.110 |
Why?
|
| Software | 1 | 2016 | 654 | 0.100 |
Why?
|
| Genotype | 4 | 2015 | 1851 | 0.100 |
Why?
|
| Micronutrients | 1 | 2011 | 17 | 0.100 |
Why?
|
| Vertigo | 1 | 2012 | 42 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1047 | 0.100 |
Why?
|
| Ultrasonography | 2 | 2013 | 695 | 0.100 |
Why?
|
| Klebsiella Infections | 1 | 2012 | 25 | 0.100 |
Why?
|
| Gases | 1 | 2012 | 30 | 0.100 |
Why?
|
| Emphysema | 1 | 2012 | 22 | 0.100 |
Why?
|
| Radiography, Abdominal | 1 | 2012 | 71 | 0.100 |
Why?
|
| Ventricular Function, Right | 1 | 2012 | 142 | 0.100 |
Why?
|
| Public Sector | 1 | 2011 | 12 | 0.100 |
Why?
|
| Private Sector | 1 | 2011 | 19 | 0.100 |
Why?
|
| C-Reactive Protein | 2 | 2010 | 190 | 0.100 |
Why?
|
| Chlamydia trachomatis | 2 | 2001 | 14 | 0.100 |
Why?
|
| Steroids | 1 | 2012 | 177 | 0.100 |
Why?
|
| Vascular Diseases | 1 | 2012 | 121 | 0.100 |
Why?
|
| Birth Order | 1 | 2010 | 8 | 0.100 |
Why?
|
| Hepatitis B virus | 1 | 2010 | 43 | 0.100 |
Why?
|
| Bioprosthesis | 1 | 2010 | 36 | 0.090 |
Why?
|
| Cell Line, Tumor | 2 | 2014 | 2426 | 0.090 |
Why?
|
| Hepatitis B | 1 | 2010 | 74 | 0.090 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2010 | 107 | 0.090 |
Why?
|
| Graft Rejection | 2 | 2010 | 1065 | 0.090 |
Why?
|
| World Health Organization | 1 | 2010 | 103 | 0.090 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2010 | 24 | 0.090 |
Why?
|
| Hong Kong | 3 | 2021 | 45 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2013 | 244 | 0.090 |
Why?
|
| Blood Proteins | 1 | 2010 | 144 | 0.090 |
Why?
|
| Patient Discharge | 1 | 2012 | 300 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 3 | 2012 | 746 | 0.090 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 1 | 2008 | 8 | 0.080 |
Why?
|
| Population Groups | 1 | 2008 | 41 | 0.080 |
Why?
|
| Transplantation Tolerance | 1 | 2010 | 130 | 0.080 |
Why?
|
| China | 3 | 2007 | 228 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2011 | 238 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 2438 | 0.080 |
Why?
|
| Pulmonary Artery | 1 | 2010 | 306 | 0.080 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2010 | 228 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2016 | 2601 | 0.080 |
Why?
|
| Emergency Service, Hospital | 1 | 2012 | 484 | 0.080 |
Why?
|
| Acculturation | 1 | 2008 | 14 | 0.080 |
Why?
|
| Autoimmune Diseases | 2 | 2008 | 241 | 0.080 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2010 | 208 | 0.080 |
Why?
|
| Hypersensitivity | 1 | 2009 | 154 | 0.080 |
Why?
|
| Interviews as Topic | 2 | 2007 | 319 | 0.080 |
Why?
|
| Primary Health Care | 1 | 2011 | 339 | 0.080 |
Why?
|
| Chemokines | 1 | 2007 | 73 | 0.080 |
Why?
|
| Cytokines | 2 | 2010 | 776 | 0.080 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2008 | 109 | 0.080 |
Why?
|
| Chromosomes, Human, 16-18 | 1 | 2007 | 26 | 0.080 |
Why?
|
| Cocarcinogenesis | 1 | 2007 | 12 | 0.080 |
Why?
|
| Chromosomes, Human, 13-15 | 1 | 2007 | 32 | 0.080 |
Why?
|
| Emigrants and Immigrants | 1 | 2008 | 44 | 0.070 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2006 | 20 | 0.070 |
Why?
|
| Receptors, Androgen | 1 | 2007 | 113 | 0.070 |
Why?
|
| Child | 7 | 2013 | 6927 | 0.070 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 567 | 0.070 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2006 | 17 | 0.070 |
Why?
|
| Q Fever | 1 | 2006 | 8 | 0.070 |
Why?
|
| Sex Distribution | 1 | 2007 | 173 | 0.070 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 33 | 0.070 |
Why?
|
| Heparitin Sulfate | 2 | 2022 | 27 | 0.070 |
Why?
|
| STAT3 Transcription Factor | 1 | 2006 | 78 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2021 | 916 | 0.070 |
Why?
|
| Mesothelioma | 2 | 1990 | 311 | 0.070 |
Why?
|
| Seasons | 1 | 2007 | 223 | 0.070 |
Why?
|
| Health Behavior | 1 | 2007 | 183 | 0.070 |
Why?
|
| Immunotherapy | 3 | 2019 | 629 | 0.070 |
Why?
|
| Population Surveillance | 1 | 2007 | 219 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 2 | 2010 | 1376 | 0.070 |
Why?
|
| Arteriosclerosis | 2 | 2002 | 113 | 0.070 |
Why?
|
| Health Fairs | 1 | 2005 | 2 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2005 | 59 | 0.070 |
Why?
|
| Mice | 5 | 2014 | 11352 | 0.060 |
Why?
|
| Internal-External Control | 1 | 2005 | 44 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2007 | 377 | 0.060 |
Why?
|
| Employment | 1 | 2005 | 52 | 0.060 |
Why?
|
| Income | 1 | 2005 | 75 | 0.060 |
Why?
|
| Hyaluronic Acid | 1 | 1984 | 49 | 0.060 |
Why?
|
| Kansas | 1 | 2004 | 6 | 0.060 |
Why?
|
| Child, Preschool | 4 | 2013 | 3612 | 0.060 |
Why?
|
| Minnesota | 1 | 2004 | 46 | 0.060 |
Why?
|
| Mammography | 1 | 2007 | 463 | 0.060 |
Why?
|
| Sigmoidoscopy | 1 | 2004 | 36 | 0.060 |
Why?
|
| Hypertension | 4 | 2012 | 1141 | 0.060 |
Why?
|
| Recurrence | 2 | 2021 | 1139 | 0.060 |
Why?
|
| Neoplasms | 1 | 2019 | 2898 | 0.060 |
Why?
|
| Air Pollutants, Occupational | 1 | 2003 | 6 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2016 | 2705 | 0.060 |
Why?
|
| Eggs | 1 | 2003 | 12 | 0.060 |
Why?
|
| Stroke | 1 | 2012 | 965 | 0.060 |
Why?
|
| Hypercalcemia | 2 | 2021 | 59 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2013 | 3362 | 0.060 |
Why?
|
| Clarithromycin | 1 | 2002 | 7 | 0.060 |
Why?
|
| Construction Materials | 1 | 2002 | 1 | 0.050 |
Why?
|
| Metallurgy | 1 | 2002 | 2 | 0.050 |
Why?
|
| Asbestosis | 1 | 2002 | 5 | 0.050 |
Why?
|
| Asbestos, Crocidolite | 1 | 2002 | 2 | 0.050 |
Why?
|
| Mining | 1 | 2002 | 3 | 0.050 |
Why?
|
| Chlamydophila Infections | 1 | 2002 | 3 | 0.050 |
Why?
|
| Transportation | 1 | 2002 | 18 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2006 | 873 | 0.050 |
Why?
|
| Olfaction Disorders | 1 | 2003 | 62 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2002 | 27 | 0.050 |
Why?
|
| Longitudinal Studies | 4 | 2007 | 1019 | 0.050 |
Why?
|
| Lamin Type A | 1 | 2022 | 24 | 0.050 |
Why?
|
| Germ Cells | 1 | 2022 | 126 | 0.050 |
Why?
|
| HLA-B27 Antigen | 1 | 2001 | 8 | 0.050 |
Why?
|
| Protein Array Analysis | 1 | 2021 | 50 | 0.050 |
Why?
|
| Calcium Chloride | 1 | 2001 | 9 | 0.050 |
Why?
|
| Aging | 1 | 2006 | 691 | 0.050 |
Why?
|
| Spinal Cord Compression | 1 | 2021 | 27 | 0.050 |
Why?
|
| Review Literature as Topic | 1 | 2001 | 21 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2021 | 50 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2005 | 912 | 0.050 |
Why?
|
| Computational Biology | 2 | 2015 | 528 | 0.050 |
Why?
|
| Cardiovascular Diseases | 2 | 2007 | 827 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 280 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2021 | 91 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 193 | 0.050 |
Why?
|
| Disease-Free Survival | 2 | 2014 | 1204 | 0.050 |
Why?
|
| Frail Elderly | 1 | 2021 | 71 | 0.050 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2021 | 376 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2000 | 54 | 0.050 |
Why?
|
| Propylene Glycols | 1 | 2000 | 30 | 0.050 |
Why?
|
| Nasopharynx | 1 | 2000 | 47 | 0.050 |
Why?
|
| Family | 2 | 2016 | 311 | 0.050 |
Why?
|
| Yersinia Infections | 1 | 2000 | 5 | 0.050 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2000 | 47 | 0.050 |
Why?
|
| Disease Models, Animal | 3 | 2002 | 2232 | 0.050 |
Why?
|
| Antibodies, Viral | 1 | 2021 | 293 | 0.050 |
Why?
|
| Transcriptional Elongation Factors | 1 | 2020 | 23 | 0.050 |
Why?
|
| Karyotyping | 1 | 2020 | 250 | 0.050 |
Why?
|
| Yersinia enterocolitica | 1 | 2000 | 18 | 0.050 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2001 | 315 | 0.050 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2001 | 112 | 0.050 |
Why?
|
| Iliac Artery | 1 | 2000 | 35 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2001 | 3092 | 0.050 |
Why?
|
| Geriatric Assessment | 1 | 2021 | 166 | 0.050 |
Why?
|
| Infant | 3 | 2012 | 3046 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2000 | 88 | 0.050 |
Why?
|
| Azithromycin | 1 | 1999 | 13 | 0.050 |
Why?
|
| Aorta, Abdominal | 1 | 2000 | 60 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2000 | 229 | 0.040 |
Why?
|
| Endothelium, Vascular | 1 | 2002 | 435 | 0.040 |
Why?
|
| Arthritis, Infectious | 1 | 1999 | 16 | 0.040 |
Why?
|
| Fractures, Bone | 1 | 2021 | 131 | 0.040 |
Why?
|
| Antigens, Bacterial | 1 | 2000 | 134 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2021 | 456 | 0.040 |
Why?
|
| Mastectomy | 1 | 2021 | 243 | 0.040 |
Why?
|
| Women's Health | 2 | 2008 | 100 | 0.040 |
Why?
|
| Haplotypes | 2 | 2014 | 642 | 0.040 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 33 | 0.040 |
Why?
|
| Precancerous Conditions | 1 | 2000 | 196 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2003 | 1673 | 0.040 |
Why?
|
| Glioma | 1 | 2001 | 285 | 0.040 |
Why?
|
| Epigenomics | 1 | 2019 | 100 | 0.040 |
Why?
|
| Antigens, CD | 1 | 2000 | 458 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 879 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 197 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 479 | 0.040 |
Why?
|
| Diabetic Angiopathies | 1 | 1997 | 62 | 0.040 |
Why?
|
| International Cooperation | 2 | 2008 | 127 | 0.040 |
Why?
|
| Hypertriglyceridemia | 1 | 1997 | 67 | 0.040 |
Why?
|
| ROC Curve | 1 | 2019 | 752 | 0.040 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2016 | 4 | 0.040 |
Why?
|
| Transmembrane Activator and CAML Interactor Protein | 1 | 2016 | 8 | 0.040 |
Why?
|
| Algorithms | 2 | 2016 | 1830 | 0.040 |
Why?
|
| Hypercholesterolemia | 1 | 1997 | 161 | 0.040 |
Why?
|
| Asia | 1 | 2016 | 95 | 0.040 |
Why?
|
| Milk | 1 | 1996 | 53 | 0.040 |
Why?
|
| Rabbits | 3 | 2002 | 636 | 0.030 |
Why?
|
| Antibodies, Bacterial | 3 | 2006 | 95 | 0.030 |
Why?
|
| Barbering | 1 | 2015 | 1 | 0.030 |
Why?
|
| Textile Industry | 1 | 2015 | 2 | 0.030 |
Why?
|
| Body Weight | 2 | 2008 | 459 | 0.030 |
Why?
|
| Time Factors | 3 | 2013 | 5210 | 0.030 |
Why?
|
| Aorta | 3 | 2002 | 280 | 0.030 |
Why?
|
| Cooking | 1 | 1996 | 55 | 0.030 |
Why?
|
| Rats | 3 | 2012 | 3990 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2000 | 977 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2001 | 763 | 0.030 |
Why?
|
| Biomarkers | 2 | 2013 | 1718 | 0.030 |
Why?
|
| Butyrophilins | 1 | 2015 | 22 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2016 | 2261 | 0.030 |
Why?
|
| Heart Transplantation | 1 | 2000 | 705 | 0.030 |
Why?
|
| Linear Models | 2 | 2007 | 421 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2019 | 395 | 0.030 |
Why?
|
| Immunohistochemistry | 3 | 2010 | 1753 | 0.030 |
Why?
|
| Survival Rate | 2 | 2013 | 1863 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 1995 | 286 | 0.030 |
Why?
|
| Likelihood Functions | 1 | 2014 | 251 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 806 | 0.030 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 996 | 0.030 |
Why?
|
| Infant, Newborn | 2 | 2011 | 2379 | 0.030 |
Why?
|
| Social Class | 1 | 2014 | 128 | 0.030 |
Why?
|
| Maintenance Chemotherapy | 1 | 2013 | 76 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 369 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2016 | 403 | 0.030 |
Why?
|
| Apoptosis | 1 | 2000 | 1683 | 0.030 |
Why?
|
| Salmonella Food Poisoning | 1 | 1992 | 4 | 0.030 |
Why?
|
| Arthritis, Reactive | 1 | 1992 | 2 | 0.030 |
Why?
|
| Infectious Mononucleosis | 1 | 2012 | 6 | 0.030 |
Why?
|
| Registries | 2 | 2011 | 702 | 0.030 |
Why?
|
| Reproductive Physiological Phenomena | 1 | 2012 | 4 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 153 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2006 | 1041 | 0.030 |
Why?
|
| National Health Programs | 1 | 2012 | 20 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2013 | 150 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2012 | 60 | 0.030 |
Why?
|
| Flank Pain | 1 | 2012 | 5 | 0.030 |
Why?
|
| Xanthophylls | 1 | 2011 | 2 | 0.030 |
Why?
|
| Cryptoxanthins | 1 | 2011 | 2 | 0.030 |
Why?
|
| Ceftriaxone | 1 | 2012 | 9 | 0.030 |
Why?
|
| Edible Grain | 1 | 2011 | 9 | 0.030 |
Why?
|
| Rupture, Spontaneous | 1 | 2012 | 43 | 0.030 |
Why?
|
| Abdominal Abscess | 1 | 2012 | 22 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2012 | 69 | 0.030 |
Why?
|
| Headache | 1 | 2012 | 73 | 0.030 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 158 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2014 | 1074 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2011 | 27 | 0.020 |
Why?
|
| Nutrition Surveys | 1 | 2011 | 114 | 0.020 |
Why?
|
| Diagnosis, Differential | 2 | 2006 | 1565 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2013 | 238 | 0.020 |
Why?
|
| Alleles | 1 | 2014 | 1128 | 0.020 |
Why?
|
| Drainage | 1 | 2012 | 157 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2010 | 22 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2010 | 1981 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 3968 | 0.020 |
Why?
|
| Abdominal Pain | 1 | 2012 | 137 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 576 | 0.020 |
Why?
|
| Respiratory Tract Infections | 1 | 2011 | 105 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2010 | 135 | 0.020 |
Why?
|
| Sheep | 1 | 2010 | 239 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1239 | 0.020 |
Why?
|
| Tumor Necrosis Factor Ligand Superfamily Member 14 | 1 | 2010 | 14 | 0.020 |
Why?
|
| Community Health Services | 1 | 2011 | 80 | 0.020 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 13 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2010 | 127 | 0.020 |
Why?
|
| Siblings | 1 | 2010 | 111 | 0.020 |
Why?
|
| Cryopreservation | 1 | 2010 | 69 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2011 | 109 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2009 | 87 | 0.020 |
Why?
|
| Isoantibodies | 1 | 2010 | 114 | 0.020 |
Why?
|
| Aorta, Thoracic | 1 | 2010 | 165 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 22 | 0.020 |
Why?
|
| Calcinosis | 1 | 2010 | 224 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2011 | 328 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1169 | 0.020 |
Why?
|
| Anemia, Hemolytic | 1 | 2008 | 19 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2013 | 1991 | 0.020 |
Why?
|
| Connecticut | 1 | 2007 | 27 | 0.020 |
Why?
|
| Body Height | 1 | 2008 | 99 | 0.020 |
Why?
|
| Demography | 1 | 2008 | 177 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 689 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2007 | 127 | 0.020 |
Why?
|
| Control Groups | 1 | 2006 | 15 | 0.020 |
Why?
|
| Ultraviolet Rays | 1 | 2008 | 193 | 0.020 |
Why?
|
| Cell Lineage | 1 | 2008 | 273 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2013 | 1204 | 0.020 |
Why?
|
| Coxiella burnetii | 1 | 2006 | 11 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2010 | 572 | 0.020 |
Why?
|
| Biological Availability | 1 | 2006 | 92 | 0.020 |
Why?
|
| Lymphatic System | 1 | 2006 | 53 | 0.020 |
Why?
|
| Blood Vessels | 1 | 2006 | 94 | 0.020 |
Why?
|
| Illinois | 1 | 2007 | 462 | 0.020 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2008 | 206 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2012 | 1351 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2007 | 677 | 0.020 |
Why?
|
| Breast | 1 | 2007 | 288 | 0.020 |
Why?
|
| Epithelium | 2 | 2000 | 319 | 0.020 |
Why?
|
| Ovarian Neoplasms | 2 | 1999 | 744 | 0.020 |
Why?
|
| Electrophoresis, Cellulose Acetate | 1 | 1984 | 3 | 0.020 |
Why?
|
| Dermatan Sulfate | 1 | 1984 | 9 | 0.020 |
Why?
|
| Proteins | 1 | 1990 | 777 | 0.020 |
Why?
|
| Celiac Disease | 1 | 2008 | 203 | 0.020 |
Why?
|
| Psoriasis | 1 | 2008 | 240 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 1984 | 47 | 0.020 |
Why?
|
| Chondroitin Sulfates | 1 | 1984 | 43 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 552 | 0.020 |
Why?
|
| Transfection | 1 | 2006 | 896 | 0.020 |
Why?
|
| Magnesium | 1 | 2005 | 177 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 1801 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2010 | 1384 | 0.010 |
Why?
|
| Electrocardiography | 1 | 2006 | 478 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 2007 | 502 | 0.010 |
Why?
|
| Azo Compounds | 1 | 2002 | 13 | 0.010 |
Why?
|
| Sarcoma | 1 | 1984 | 215 | 0.010 |
Why?
|
| Cholesterol, Dietary | 1 | 2002 | 27 | 0.010 |
Why?
|
| Biotransformation | 1 | 2002 | 50 | 0.010 |
Why?
|
| Coloring Agents | 1 | 2002 | 64 | 0.010 |
Why?
|
| Tunica Intima | 1 | 2002 | 59 | 0.010 |
Why?
|
| Radioimmunotherapy | 1 | 2002 | 25 | 0.010 |
Why?
|
| Vaccines, DNA | 1 | 2001 | 16 | 0.010 |
Why?
|
| Molecular Mimicry | 1 | 2001 | 20 | 0.010 |
Why?
|
| Histocompatibility Antigens | 1 | 2001 | 35 | 0.010 |
Why?
|
| HLA-A2 Antigen | 1 | 2001 | 31 | 0.010 |
Why?
|
| Rats, Inbred Lew | 1 | 2001 | 186 | 0.010 |
Why?
|
| Dilatation, Pathologic | 1 | 2001 | 54 | 0.010 |
Why?
|
| Tobacco, Smokeless | 1 | 2001 | 10 | 0.010 |
Why?
|
| Rheumatic Diseases | 1 | 2001 | 20 | 0.010 |
Why?
|
| Plants, Toxic | 1 | 2001 | 26 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2001 | 88 | 0.010 |
Why?
|
| Immunization | 1 | 2001 | 158 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2001 | 213 | 0.010 |
Why?
|
| Animals, Genetically Modified | 1 | 2001 | 181 | 0.010 |
Why?
|
| Echocardiography | 1 | 2006 | 911 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2002 | 231 | 0.010 |
Why?
|
| Rats, Inbred BN | 1 | 2000 | 37 | 0.010 |
Why?
|
| Rats, Inbred WKY | 1 | 2000 | 31 | 0.010 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2000 | 29 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2000 | 85 | 0.010 |
Why?
|
| Sphingosine | 1 | 2000 | 71 | 0.010 |
Why?
|
| Spleen | 1 | 2001 | 430 | 0.010 |
Why?
|
| Phagocytes | 1 | 2000 | 10 | 0.010 |
Why?
|
| Antigen Presentation | 1 | 2001 | 209 | 0.010 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2000 | 43 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2000 | 66 | 0.010 |
Why?
|
| Calcium | 1 | 2005 | 1156 | 0.010 |
Why?
|
| Prosthesis Failure | 1 | 2000 | 111 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2000 | 149 | 0.010 |
Why?
|
| Rectum | 1 | 2000 | 146 | 0.010 |
Why?
|
| Databases as Topic | 1 | 1999 | 92 | 0.010 |
Why?
|
| Device Removal | 1 | 2000 | 161 | 0.010 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 728 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2001 | 729 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2000 | 278 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2000 | 143 | 0.010 |
Why?
|
| Acute Disease | 1 | 2000 | 826 | 0.010 |
Why?
|
| Interferon-gamma | 1 | 2000 | 444 | 0.010 |
Why?
|
| Rural Population | 1 | 1998 | 136 | 0.010 |
Why?
|
| Disabled Persons | 1 | 1998 | 67 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 2818 | 0.010 |
Why?
|
| Receptors, Urokinase Plasminogen Activator | 1 | 1995 | 21 | 0.010 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1995 | 47 | 0.010 |
Why?
|
| Molecular Weight | 1 | 1995 | 332 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2000 | 1924 | 0.010 |
Why?
|
| Blotting, Western | 1 | 1995 | 782 | 0.010 |
Why?
|
| Salmonella enteritidis | 1 | 1992 | 4 | 0.010 |
Why?
|
| Histocompatibility Testing | 1 | 1992 | 154 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 1984 | 2262 | 0.010 |
Why?
|
| Antibody Formation | 1 | 1992 | 171 | 0.010 |
Why?
|
| Immunity, Cellular | 1 | 1992 | 177 | 0.010 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1990 | 12 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1990 | 155 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2000 | 2207 | 0.010 |
Why?
|
| Testicular Neoplasms | 1 | 1990 | 105 | 0.010 |
Why?
|
| Peritoneal Neoplasms | 1 | 1990 | 177 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 1990 | 669 | 0.000 |
Why?
|